Regional Variation in Utilization of Hepatitis C-Positive Organs for Heart Transplantation in the United States

With increasing organs available in light of the national opioid epidemic and the availability of direct acting-antiviral (DAA) therapy for Hepatitis C virus (HCV), HCV antibody (Ab)+ organs serve as an important potential supply to the donor pool. We sought to examine trends over time in the utilization of HCV Ab+ organs both nationally and regionally.

Source: The Journal of Heart and Lung Transplantation - March 16, 2019 Category: Transplant Surgery Authors: E.M. DeFilippis, A.R. Garan, R.C. Givens, L.K. Truby, F. Latif, S.W. Restaino, K. Takeda, H. Takayama, Y. Naka, P.C. Colombo, M.A. Farr, V.K. Topkara Tags: 97 Source Type: research